Bisphosphonate: Class Overview and Comparison
Quick answer: Bisphosphonate are a class of medicines used for specific therapeutic indications. iMedic covers 11 bisphosphonate substances. Below is a comparison table linking to detailed pages for each.
Bisphosphonate on iMedic (11 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Alendronat Aristo Veckotablett | Osteoporosis, Prevention of osteoporotic fractures | Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bon | 70 mg once weekly |
| Alendronat Aurobindo Veckotablett | Osteoporosis, Prevention of osteoporotic fractures | Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bon | 70 mg once weekly |
| Alendronate | Osteoporosis, Paget's disease of bone | Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bon | 10 mg daily or 70 mg once weekly |
| Iasibon | Bone metastases from breast cancer, Tumor-induced hypercalcemia | Ibandronic acid, a nitrogen-containing bisphosphonate that inhibits osteoclast-m | 6 mg IV every 3-4 weeks or 50 mg orally once daily |
| Ibandronate | Postmenopausal osteoporosis, Bone metastases from breast cancer | Nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorp | 150 mg orally once monthly or 3 mg IV every 3 months |
| Ibandronic Acid | Postmenopausal osteoporosis, Bone metastases from breast cancer | Nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorp | 150 mg orally once monthly or 3 mg IV every 3 months |
| Optinate | Osteoporosis, Paget's disease of bone | Nitrogen-containing bisphosphonate (risedronate) inhibiting osteoclast-mediated | 5 mg daily or 35 mg once weekly orally |
| Optinate Septimum | Postmenopausal osteoporosis | Weekly-dosed risedronate sodium formulation inhibiting osteoclast-mediated bone | 35 mg once weekly orally |
| Pamidronatdinatrium Pfizer | Hypercalcemia of malignancy, Bone metastases | Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite | 30-90 mg IV infusion |
| Pamifos | Hypercalcemia of malignancy, Bone metastases | Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite | 30-90 mg IV infusion |
| Risedronat | Osteoporosis, Paget's disease of bone | Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bon | 5 mg daily or 35 mg weekly |
About Bisphosphonate
Bisphosphonate share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Bisphosphonate?
Bisphosphonate are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 11 substances in this class with detailed pages for each.
Are all Bisphosphonate interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Bisphosphonate?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Bisphosphonate available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.